Mutated RIG-I receptor causes kidney inflammation through Y-RNA activation

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.

RIG-I is an important sensor in the innate immune system that recognizes viral RNA and activates the antiviral defense. However, certain changes in the genetic material, known as mutations, can make RIG-I hypersensitive, causing the immune receptor to mistake the body's own RNA for viral intruders. The research team found that mice carrying a RIG-I E373A mutation associated with patients spontaneously developed lupus-like nephritis, a severe and often fatal kidney inflammation. In contrast to classic lupus, in which inflammation occurs due to deposits of immune complexes, the disease in these mice was caused by direct kidney inflammation triggered by the mutated RIG-I.

Hidden, tissue-specific activator of autoimmune inflammation

Further investigations showed that a short, non-coding RNA known as Y-RNA, which is produced in large quantities in the kidney, binds directly to the mutated RIG-I and triggers its abnormal activation.

We discovered that Y-RNA acts like a false alarm for the mutated RIG-I receptor, especially in kidney cells. This local malfunction of the immune system triggers severe inflammation similar to human lupus nephritis."

Prof. Hiroki Kato, corresponding author, Director of the Institute for Cardiovascular Immunology at UKB and member of the ImmunoSensation Cluster of Excellence2 at the University of Bonn

From molecular insights to the disease mechanism

"Using advanced molecular and structural analyses, we were able to show that the RIG-I-E373A mutant binds to Y-RNA in an unusual way, which leads to activation of the receptor even without viral infection," says first author Saya Satoh, a doctoral student at the University of Bonn in Prof. Kato's research group at the UKB. "This abnormal activation caused the kidney cells to produce large amounts of interferons and chemokines, which attracted immune cells and triggered inflammation." However, the researchers were also able to identify a potential therapeutic target: blocking the so-called CCR2 signaling pathway, which recruits monocytes belonging to the white blood cells, significantly reduces kidney inflammation in the affected mice.

Impact on autoimmune diseases

Mutations in RIG-I have been linked to rare hereditary diseases such as Singleton-Merten syndrome (SMS) and systemic lupus erythematosus (SLE). This study provides important insights into how such mutations can selectively damage organs such as the kidney. These findings could pave the way for the development of targeted therapies that block the activation of mutated RIG-I or its interacting Y RNAs.

Participating institutions and funding:

In addition to the UKB and the University of Bonn, the following institutions were involved in the study: Nanyang Technological University, Singapore, University Hospital Würzburg, Germany, Okayama University, Japan, Kyoto University, Japan. The project was supported by the DFG, the German Excellence Strategy EXC 2151 "Nucleic Acid Immunity – Collaborative Research Center TRR237," Open Philanthropy as part of the PANDEMIC ANTIVIRAL DISCOVERY PARTNERSHIP, and the Singapore Ministry of Education MOE AcRF Tier 1 Award.

Source:
Journal reference:

Satoh, S., et al. (2025) Local activation of mutant RIG-I by short noncoding Y-RNA in the kidney triggers lethal nephritis. Science Immunology. doi.org/10.1126/sciimmunol.adx1135

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Targeted therapy combination shows superior outcomes in advanced kidney cancer